Glenmark Pharma Launches Authorized Generic of INLYTA Tablets in the US
Glenmark Pharmaceuticals Ltd 路 Press Release 路 16 Nov 2026, 2:10 pm
Glenmark Pharma Launches Authorized Generic of INLYTA Tablets in the US Glenmark Pharmaceuticals Inc., USA launched Axitinib Tablets (1 mg and 5 mg), an Authorized Generic version of Pfizer's INLYTA tablets, in the US market on 16th Nov'26. According to IQVIA sales data for the 12-month period ending Sep'26, INLYTA achieved annual US sales of approximately $538.4 million. The launch strengthens Glenmark's North American oncology and generic portfolio, targeting a substantial market opportunity.
Original exchange filing (PDF)
More announcements from Glenmark Pharmaceuticals Ltd
- Ichnos Glenmark Innovation (IGI) announces IND submission to US FDA for ISB 2301 路 18 Nov 2026
- Schedule of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Initmation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst/ Institutional Investor Meetings 路 10 Nov 2026
- Intimation of Schedule of Analyst / Institutional Investor Meetings 路 10 Nov 2026
- Transcript of the Earnings Call 路 09 Nov 2026
- Audio recording of Q2 FY 2026-27 Earnings Call held on November 06, 2026 路 06 Nov 2026
- Investor Presentation for the quarter and half year ended September 30, 2026 路 05 Nov 2026
